Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer

Journal of Clinical Oncology

Volumn 33, Issue 7, 2015, Pages 716-722

  Bekelman, Justin E ^c   Mitra, Nandita ^c   Handorf, Elizabeth A ^a   Uzzo, Robert G ^a   Hahn, Stephen A ^c   Polsky, Daniel ^c   Armstrong, Katrina ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONFIDENCE INTERVAL; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; INSTRUMENTAL VARIABLE ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPENSITY SCORE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER GRADING; CANCER REGISTRY; COMPARATIVE STUDY; EPIDEMIOLOGY; MEDICARE; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS; UNITED STATES;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; MEDICARE; NEOPLASM GRADING; PROPENSITY SCORE; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES;

EID: 84921356820     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.2743     Document Type: Article

References (33)

1. Lu-Yao GL, Albertsen PC, Moore DF, et al: Outcomes of localized prostate cancer following conservative management. JAMA 302:1202-1209, 2009
2. Daskivich TJ, Fan KH, Koyama T, et al: Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med 158:709-717, 2013
3. Widmark A, Klepp O, Solberg A, et al: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 373:301-308, 2009
4. Warde P, Mason M, Ding K, et al: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. Lancet 378:2104-2111, 2011
5. Lu-Yao GL, Albertsen PC, Moore DF, et al: Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300:173-181, 2008
6. Roberts CB, Albertsen PC, Shao YH, et al: Patterns and correlates of prostate cancer treatment in older men. Am J Med 124:235-243, 2011
7. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448-4456, 2006
8. Jacobsen L, Mather M, Lee M, et al: America's Aging Population. http://www.prb.org/pdf11/aging-in-america.pdf
9. Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
10. Shahinian VB, Kuo YF, Gilbert SM: Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 363:1822-1832, 2010
11. Bekelman JE, Mitra N, Efstathiou J, et al: Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 81: e325-e334, 2011
12. Shahinian VB, Kuo YF, Freeman JL, et al: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164, 2005
13. Elixhauser A, Steiner C, Harris D, et al: Comorbidity measures for use with administrative data. Med Care 36:8-27, 1998
14. Mattei A: Estimating and using propensity score in presence of missing background data: An application to assess the impact of childbearing on wellbeing. Stat Methods Appt 18:257-273, 2009
15. Rosenbaum P, Robin D: Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79:516-524, 1984
16. Rosenbaum P, Rubin D: The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55, 1983
17. Rubin D: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763, 1997
18. Gaynor J, Feuer E, Tan C, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
19. Fine J, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stats Assoc 94:496-509, 1999
20. Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data (ed 2). Springer, New York, NY, 2003
21. Brookhart MA, Stürmer T, Glynn RJ, et al: Confounding control in healthcare database research: Challenges and potential approaches. Med Care 48:S114-S120, 2010 (suppl)
22. Wennberg J, Gittelsohn J: Small area variations in health care delivery. Science 182:1102-1108, 1973
23. Terza JV, Basu A, Rathouz PJ: Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling. J Health Econ 27:531-543, 2008
24. Clogg CC, Petkova E, Haritou A: Statistical methods for comparing regression coefficients between models. Am J Sociol 100:1271-1293, 1995
25. Spillman B: Changes in elderly disability rates and the implications for health care utilization and cost. Milbank Q 82:157-194, 2004
26. Bechis SK, Carroll PR, Cooperberg MR: Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 29:235-241, 2011
27. Wong YN, Mitra N, Hudes G, et al: Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 296: 2683-2693, 2006
28. Potosky AL, Haque R, Cassidy-Bushrow AE, et al: Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol 32:1324-1330, 2014
29. Hill AB: The environment and disease: Association or causation? Proc R Soc Med 58:295-300, 1965
30. Tan A, Parker C: Radiotherapy in locally advanced prostate cancer. Lancet 373:274-276, 2009
31. Albertsen PC, Walters S, Hanley JA: A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol 163:519-523, 2000
32. Penson DF, Albertsen PC, Nelson PS, et al: Determining cause of death in prostate cancer: Are death certificates valid? J Natl Cancer Inst 93:1822-1823, 2001
33. Angrist J, Imbens G, Rubin D: Identification of causal effects using instrumental variables. J Am Stat Assoc 91:444-455, 1996